Epidemiology of Multiple Sclerosis

Neurologic Clinics

Volumn 34, Issue 4, 2016, Pages 919-939

  Howard, Jonathan ^a   Trevick, Stephen ^b   Younger, David S ^c  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multiple sclerosis; Neuroepidemiology; Public health

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BETA INTERFERON; CORTICOTROPIN; FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; MITOXANTRONE; NATALIZUMAB; POTASSIUM CHANNEL BLOCKING AGENT; STEROID;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ASIA; CLINICAL EXAMINATION; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISABILITY; ETHNICITY; EUROPE; GENOME-WIDE ASSOCIATION STUDY; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MENTAL HEALTH CARE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATHOPHYSIOLOGY; PATIENT CARE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; WESTERN HEMISPHERE;

HUMANS; MULTIPLE SCLEROSIS;

EID: 84991777017     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2016.06.016     Document Type: Review

References (130)

1. Poser, C.M., Brinar, V.V., The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology 29 (2007), 150–155.
2. Poser, C., Clinical diagnostic criteria in epidemiological studies of multiple sclerosis. Ann N Y Acad Sci 122 (1965), 506–519.
3. Evans, C., Beland, S.-G., Kulaga, S., et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 40 (2013), 195–210.
4. Helmick, C., Wrigley, J., Zack, M., et al. Multiple sclerosis in Key West, Florida. Am J Epidemiol 130 (1989), 935–949.
5. Wynn, D., Rodriguez, M., O'Fallon, W., et al. A reappraisal of the epidemiology of multiple sclerosis in Olmstead County, Minnesota. Neurology 40 (1990), 780–786.
6. Hopkins, R., Indian, R., Pinnow, E., et al. Multiple sclerosis in Galion, Ohio: prevalence and results of a case-control study. Neuroepidemiology 10 (1991), 192–199.
7. Mayr, W., Pittock, S., McClelland, R., et al. Incidence and prevalence of multiple sclerosis in Olmstead County, Minnesota, 1985-2000. Neurology 61 (2003), 1373–1377.
8. Neuberger, J., Lynch, S., Sutton, M., et al. Prevalence of multiple sclerosis in a residential area bordering an oil refinery. Neurology 63 (2004), 1796–1802.
9. Cowen, J., Sjostrom, B., Doughty, A., et al. Case-finding for MS prevalence studies in small communities requires a community-based approach. Neuroepidemiology 28 (2007), 246–252.
10. Williamson, D., Henry, J., Schiffer, R., et al. Prevalence of multiple sclerosis in 19 Texas counties, 1998-2000. J Environ Health 69 (2007), 41–45.
11. Turabelidze, G., Schootman, M., Zhu, B., et al. Multiple sclerosis prevalence and possible lead exposure. J Neurol Sci 269 (2008), 158–162.
12. Noonan, C., Williamson, D., Henry, J., et al. The prevalence of multiple sclerosis in 3 US communities. [abstract] Prev Chronic Dis, 7, 2010, A1.
13. Pryse-Phillips, W., The incidence and prevalence of multiple sclerosis in Newfoundland and Labrador, 1960-1986. Ann Neurol 20 (1986), 323–328.
14. Warren, S., Warren, K., Prevalence of multiple sclerosis in Barrhead County, Alberta, Canada. Can J Neurol Sci 19 (1992), 72–75.
15. Warren, S., Warren, K., Prevalence, incidence, and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology 43 (1993), 1760–1763.
16. Klein, G., Rose, M., Seland, T., A prevalence study of multiple sclerosis in the Crownest Pass region of Southern Alberta. Can J Neurol Sci 21 (1994), 262–265.
17. Svenson, L., Woodhead, S., Platt, G., Regional variations in the prevalence rates of multiple sclerosis in the province of Alberta, Canada. Neuroepidemiology 13 (1994), 8–13.
18. Mirsattari, S., Johnston, J., McKenna, R., et al. Aboriginal with multiple sclerosis HLA type and predominance of neuromyelitis optica. Neurology 56 (2001), 317–323.
19. Beck, C., Metz, L., Svenson, I., et al. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 11 (2005), 516–519.
20. Sloka, J., Pryse-Phillips, W., Stefanelle, M., Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Can J Neurol Sci 32 (2005), 37–42.
21. Svenson, L., Warren, S., Warren, K., et al. Prevalence of multiple sclerosis in First Nations people of Alberta. Can J Neurol Sci 34 (2007), 175–180.
22. Hader, W., Yee, I., Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology 69 (2007), 1224–1229.
23. Warren, S., Svenson, L., Warren, K., Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler 14 (2008), 872–879.
24. Marrie, R., Yu, N., Blanchard, J., et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 74 (2010), 465–471.
25. Warren, S., Svenson, L., Warren, K., et al. Incidence of multiple sclerosis among First Nations people in Alberta, Canada. Neuroepidemiology 28 (2007), 21–27.
26. Callegaro, D., Amaro De Lolio, C., Radvany, J., et al. Prevalence of multiple sclerosis in the city of Sao Paulo, Brazil, in 1990. Neuroepidemiology 11 (1992), 11–14.
27. Callegaro, D., Goldbaum, M., Morais, L., et al. The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil. Acta Neurol Scand 104 (2001), 208–213.
28. Toro, J., Sarmiento, O., Diaz del Castillo, A., et al. Prevalence of multiple sclerosis in Bogota, Colombia. Neuroepidemiology 28 (2007), 33–38.
29. Melcon, M., Gold, L., Carra, A., et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis. Mult Scler 14 (2008), 656–662.
30. Cristiano, C., Patrucco, L., Rojas, J., et al. Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method. Eur J Neurol 16 (2009), 183–187.
31. Gracia, F., Castillo, L., Benzadon, A., et al. Prevalence and incidence of multiple sclerosis in Panama (2000-2005). Neuroepidemiology 32 (2009), 287–293.
32. Simpson, S.J., Blizzard, L., Otahal, P., et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry 82 (2011), 1132–1141.
33. Poppe, A., Wolfson, C., Zhu, B., Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci 35 (2008), 593–601.
34. Risco, J., Maldonado, H., Luna, L., et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 17 (2011), 1055–1059.
35. Orton, S.-M., Herrera, B., Yee, I., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5 (2006), 932–936.
36. Kingwell, E., Marriott, J.J., Jette, N., et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol, 13, 2013, 128.
37. Sharpe, G., Price, S.E., Last, A., et al. Multiple sclerosis in island populations: prevalence in the Bailiwicks of Guernsey and Jersey. J Neurol Neurosurg Psychiatry 58 (1995), 22–26.
38. Rothwell, P.M., Charlton, D., High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition. J Neurol Neurosurg Psychiatry 64 (1998), 730–735.
39. Gray, O.M., McDonnell, G.V., Hawkins, S.A., Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult Scler 14 (2008), 880–886.
40. Sotgiu, S., Pugliatti, M., Sanna, A., et al. Multiple sclerosis complexity in selected populations: the challenge of Sardinia, insular Italy. Eur J Neurol 9 (2002), 329–341.
41. Casetta, I., Granieri, E., Marchi, D., et al. An epidemiological study of multiple sclerosis in central Sardinia, Italy. Acta Neurol Scand 98 (1998), 391–394.
42. Granieri, E., Casetta, I., Govoni, V., et al. The increasing incidence and prevalence of MS in a Sardinian province. Neurology 55 (2000), 842–847.
43. Montomolia, C., Allemania, C., Solinasa, G., et al. An ecologic study of geographical variation in multiple sclerosis risk in central Sardinia, Italy. Neuroepidemiology 21 (2002), 187–193.
44. Pugliatti, M., Sotgiu, S., Solinas, G., et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 103 (2001), 20–26.
45. Rosati, G., Aiello, I., Pirastru, M.I., et al. Epidemiology of multiple sclerosis in northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 15 (1996), 10–19.
46. Rosati, G., Aiello, I., Mannu, L., et al. Incidence of multiple sclerosis in the town of Sassari, Sardinia, 1965 to 1985: evidence for increasing occurrence of the disease. Neurology 38 (1988), 384–388.
47. Papathanasopoulos, P., Gourzoulidou, E., Messinis, L., et al. Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey. Neuroepidemiology 30 (2008), 167–173.
48. Makhani, N., Morrow, S.A., Fisk, J., et al. MS incidence and prevalence in Africa, Asia, Australia and New Zealand: a systematic review. Mult Scler Relat Disord 3 (2014), 48–60.
49. Al-Din, A.S., Khogali, M., Poser, C.M., et al. Epidemiology of multiple sclerosis in Arabs in Kuwait: a comparative study between Kuwaitis and Palestinians. J Neurol Sci 100 (1990), 137–141.
50. Alshubaili, A.F., Alramzy, K., Ayyad, Y.M., et al. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 53 (2005), 125–131.
51. Alter, M., Kahana, E., Zilber, N., et al. Multiple sclerosis frequency in Israel's diverse populations. Neurology 66 (2006), 1061–1066.
52. Bharucha, N.E., Bharucha, E.P., Wadia, N.H., et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology 38 (1988), 727–729.
53. Cheng, Q., Miao, L., Zhang, J., et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology 68 (2007), 1495–1500.
54. El-Salem, K., Al-Shimmery, E., Horany, K., et al. Multiple sclerosis in Jordan: a clinical and epidemiological study. J Neurol 253 (2006), 1210–1216.
55. Etemadifar, M., Janghorbani, M., Shaygannejad, V., et al. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 27 (2006), 39–44.
56. Ghandehari, K., Riasi, H.R., Nourian, A., et al. Prevalence of multiple sclerosis in north east of Iran. Mult Scler 16 (2010), 1525–1526.
57. Houzen, H., Niino, M., Hata, D., et al. Increasing prevalence and incidence of multiple sclerosis in northern Japan. Mult Scler 14 (2008), 887–892.
58. Houzen, H., Niino, M., Kikuchi, S., et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 211 (2003), 49–53.
59. Itoh, T., Aizawa, H., Hashimoto, K., et al. Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan. J Neurol Sci 214 (2003), 7–9.
60. Karni, A., Kahana, E., Zilber, N., et al. The frequency of multiple sclerosis in Jewish and Arab populations in greater Jerusalem. Neuroepidemiology 22 (2003), 82–86.
61. Kim, N.H., Kim, H.J., Cheong, H.K., et al. Prevalence of multiple sclerosis in Korea. Neurology 75 (2010), 1432–1438.
62. Lai, C.H., Tseng, H.F., Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology 33 (2009), 247–253.
63. Lau, K.K., Wong, L.K., Li, L.S., et al. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 8 (2002), 77–80.
64. Osoegawa, M., Kira, J., Fukazawa, T., et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 15 (2009), 159–173.
65. Saadatnia, M., Etemadifar, M., Maghzi, A.H., Multiple sclerosis in Isfahan, Iran. Int Rev Neurobiol 79 (2007), 357–375.
66. Sahraian, M.A., Khorramnia, S., Ebrahim, M.M., et al. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol 64 (2010), 331–336.
67. Tsai, C.P., Yuan, C.L., Yu, H.Y., et al. Multiple sclerosis in Taiwan. J Chin Med Assoc 67 (2004), 500–505.
68. Turk Boru, U., Alp, R., Sur, H., et al. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology 27 (2006), 17–21.
69. Yu, Y.L., Woo, E., Hawkins, B.R., et al. Multiple sclerosis amongst Chinese in Hong Kong. Brain 112 (1989), 1445–1467.
70. Svejgaard, A., The immunogenetics of multiple sclerosis. Immunogenetics 60 (2008), 275–286.
71. McFarland, H.F., Greenstein, F., McFarlin, D.E., et al. Family and twin studies in multiple sclerosis. Ann N Y Acad Sci 436 (1985), 118–124.
72. Ebers, G.C., Bulman, D.E., Sadovnick, A.D., et al. A population based study of multiple sclerosis in twins. N Engl J Med 315 (1986), 1638–1642.
73. Ebers, G.C., Genetics and multiple sclerosis: an overview. Ann Neurol 36 (1994), S12–S14.
74. Clinical demographics of multiplex families with multiple sclerosis. Multiple Sclerosis Genetics Group. Ann Neurol 43 (1998), 530–534.
75. Herrera, B.M., Ramagopalan, S.V., Lincoln, M.R., et al. Parent-of-origin effects in MS: observations from avuncular pairs. Neurology 1 (2008), 799–803.
76. Mumford, C.J., Wood, N.W., Kellar-Wood, H., et al. The British Isles survey of multiple sclerosis in twins. Neurology 44 (1994), 11–15.
77. Baranzini, S.E., Mudge, J., van Velkinburgh, J.C., et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464 (2010), 1351–1356.
78. Bashinskaya, V.V., Kulakova, O.G., Boyko, A.N., et al. A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-drive approaches. Hum Genet 134 (2015), 1143–1162.
79. Burdett T, Hall PN, Hasting E, et al. The NHGRI-EBI Catalog of published genome-wide association studies. Available at: http://www.ebi.ac.uk/gwas. Accessed December 15, 2015.
80. DeJager, P.L., Jia, X., Wang, J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41 (2009), 776–782.
81. De Jager, P.L., Baecher-Allan, C., Maier, L.M., et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 106 (2009), 5264–5269.
82. De Jager, P.L., Chibnik, L.B., Cui, J., et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 8 (2009), 1111–1119.
83. Patsopoulos, N.A., Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 70 (2011), 897–912.
84. Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD; OMIM Entry #126200-Multiple Sclerosis, susceptibility to; MS. World Wide Web URL. Available at: http://omim.org/DOI 5/30/16. Accessed December 15, 2015.
85. Calabresi, P.A., Fields, N.S., Farnon, E.C., et al. ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. J Neuroimmunol 85 (1998), 212–219.
86. Cox, G.M., Kithcart, A.P., Pitt, D., et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J Immunol 191 (2013), 1043–1054.
87. Langkamp, M., Hörnig, S.C., Hörnig, J.B., et al. Detection of myelin autoantibodies: evaluation of an assay system for diagnosis of multiple sclerosis in differentiation from other central nervous system diseases. Clin Chem Lab Med 47 (2009), 1395–1400.
88. Tzartos, J.S., Khan, G., Vossenkamper, A., et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 78 (2012), 15–23.
89. Willis, S.N., Stadelmann, C., Rodig, S.J., et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132 (2009), 3318–3328.
90. Sargsyan, S.A., Shearer, A.J., Ritchie, A.M., et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74 (2010), 1127–1135.
91. Kurtzke, J.F., Beebe, G.W., Norman, J.E., Epidemiology of multiple sclerosis in U.S. veterans. 1. Race, sex, and geographic distribution. Neurology 29 (1979), 1228–1235.
92. Kurtzke, J.F., Beebe, G.W., Norman, J.E., Epidemiology of multiple sclerosis in U.S. veterans. 3. Migration and the risk of MS. Neurology 35 (1985), 672–678.
93. Smith, C.R., Scheinberg, L.C., Clinical features of multiple sclerosis. Semin Neurol 5 (1985), 85–93.
94. Chung, S.E., Cheong, H.K., Park, J.H., et al. Burden of disease of multiple sclerosis in Korea. Epidemiol Health, 34, 2012, e2012008.
95. Waxman, S.G., Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 306 (1982), 1529–1533.
96. Popescu, B.F., Lucchinetti, C.F., Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol, 12, 2012, 11.
97. Wolkorte, R., Heersema, D.J., Zijdewind, I., Muscle fatigability during a sustained index finger abduction and depression scores are associated with perceived fatigue in patients with relapsing-remitting multiple sclerosis. Neurorehabil Neural Repair 8 (2015), 796–802.
98. Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 6 (1996), 907–911.
99. McAlpine, D., The benign form of multiple sclerosis: a study based on 241 cases seen with three years of onset and followed up until the tenth year or more of the disease. Brain 84 (1961), 185–203.
100. Detels, R., Clark, V.A., Valdiviezo, N.L., et al. Factors associated with a rapid course of multiple sclerosis. Arch Neurol 39 (1982), 337–341.
101. Poser, S., Kurtzke, J.F., Poser, W., et al. Survival in multiple sclerosis. J Clin Epidemiol 42 (1989), 159–168.
102. Runmarker, B., Andersen, O., Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116 (1993), 117–134.
103. Poser, C.M., Paty, D.W., Scheinberg, L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983), 227–231.
104. McDonald, W.I., Compston, A., Edan, G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001), 121–127.
105. Polman, C.H., Reingold Edan, G., Edan, G., et al. Diagnostic accuracy for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58 (2005), 840–846.
106. Dalton, C.M., Brex, P.A., Miszkiel, K.A., et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52 (2002), 47–53.
107. Montalban, X., Tintore, M., Swanton, J., et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74 (2010), 427–434.
108. CHAMPS Study Group, MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59 (2002), 998–1005.
109. Barkhof, F., Rocca, M., Francis, G., et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta-1a. Ann Neurol 53 (2002), 718–724.
110. Tintore, M., Rovira, A., Rio, J., et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60 (2003), 27–30.
111. Polman, C.H., Reingold, S.C., Banwell, B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69 (2011), 292–302.
112. Swanton, J.K., Rovira, A., Tintore, M., et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicenter retrospective study. Lancet Neurol 6 (2007), 677–686.
113. Swanton, J.K., Fernando, K., Dalton, C.M., et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 77 (2006), 830–833.
114. Inglese, M., Grossman, R.I., Filippi, M., Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution. J Neuroimaging 15:Suppl4 (2005), 22S–29S.
115. Thompson, A.J., Kaufman, P., Shortman, R.C., et al. Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis. Br Med J 1 (1979), 16–17.
116. Kostulas, V.K., Link, H., Lefvert, A.K., Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 44 (1987), 1041–1044.
117. Ingram, D.A., Thompson, A.J., Swash, M., Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J Neurol Neurosurg Psychiatry 51 (1988), 487–494.
118. Rubiera, M., Rio, J., Tintore, M., et al. Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis. Neurology 66 (2006), 1568–1570.
119. Lennon, V.A., Wingerchuk, D.M., Kryzer, T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004), 2106–2112.
120. Weinshenker, B.G., Wingerchuk, D.M., Pittock, S.J., et al. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 22 (2006), 197–206.
121. Sellner, J., Boggild, M., Clanet, M., et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17 (2010), 1010–1032.
122. Papadopoulos, M.C., Verkman, A., Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11 (2012), 535–544.
123. Jayakrishnan, M.P., Krishnakumar, P., Clinical profile of acute disseminated encephalomyelitis in children. J Pediatr Neurosci 5 (2010), 111–114.
124. Younger, D.S., Younger, A.P.J., Vasculitis and connective tissue disorders. Kalman, B., Brannagan, T.H. III, (eds.) Neuroimmunology in clinical practice, 2008, Wiley-Blackwell, Hoboken (NJ).
125. Younger, D.S., Younger, A.P.J., CNS vasculitis. Coyle, P., Rivzi, S., (eds.) Clinical neuroimmunology: multiple sclerosis and related disorders, 2011, Springer, New York.
126. Vandenbark, A.A., Chou, Y.K., Whitham, R., et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 2 (1996), 1109–1115.
127. Van Diemen, H.A.M., Polman, C.H., van Dongen, T.M., et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32 (1992), 123–130.
128. Bever, C.T., Young, D., Anderson, P.A., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44 (1994), 1054–1059.
129. Schapiro, R.T., Symptom management in multiple sclerosis. Ann Neurol 36 (1994), S123–S129.
130. Whittle, I.R., Haddow, L.J., CT guided thalamotomy for movement disorders in multiple sclerosis: problems and paradoxes. Acta Neurochir 64 (1995), S13–S16.